T3	Procedure 102 122	first-line treatment
T4	Procedure-Name 102 122	first-line treatment
E3	Procedure:T3 Name:T4
T5	Procedure 387 407	first-line treatment
T6	Procedure-Name 387 407	first-line treatment
E5	Procedure:T5 Name:T6 Temporality:E19 Temporality2:E20
T7	Eq-Value 428 432	2007
T8	Eq-Value 437 446	June 2016
T10	Eq-Comparison 481 489	previous
E6	Eq-Comparison:T10 Temporal-Period:T11
T11	Eq-Temporal-Period 481 489	previous
A1	Eq-Temporal-Period-Value T11 past
T1	Condition 81 90	carcinoma
E1	Condition:T1 Name:T2
T2	Condition-Name 81 90	carcinoma
T12	Modifier 59 80	metastatic renal cell
E2	Modifier:T12 Modifies:T2
T13	Modifier 39 55	locally advanced
E4	Modifier:T13 Modifies:T2
T14	Or 56 58	or
E7	Or:T14 Arg:E4 Arg2:E2
T15	Eq-Comparison 132 144	at least one
E8	Eq-Comparison:T15 Operator:T16 Value:T17
T16	Eq-Operator 132 140	at least
A2	Eq-Operator-Value T16 GTEQ
T17	Eq-Value 141 144	one
T18	Drug 145 166	anti-angiogenic agent
E9	Drug:T18 Minimum-Count:E8 Name:T19
R1	Using Arg1:E3 Arg2:E9	
T22	Drug 168 193	tyrosine kinase inhibitor
E12	Drug:T22 Name:T23
T23	Drug-Name 168 193	tyrosine kinase inhibitor
R3	Example-Of Arg1:E12 Arg2:E9	
T24	Drug 197 218	monoclonal antibodies
E13	Drug:T24 Name:T25
T25	Drug-Name 197 218	monoclonal antibodies
T19	Drug-Name 145 166	anti-angiogenic agent
T20	Drug 232 246	mTOR inhibitor
E10	Drug:T20 Name:T21
T21	Drug-Name 232 246	mTOR inhibitor
T26	Or 220 228	and / or
E11	Or:T26 Arg:E9 Arg2:E10
T27	Observation 278 285	ECOG-PS
E14	Observation:T27 Name:T28
T28	Observation-Name 278 285	ECOG-PS
T29	Observation 293 346	Eastern Cooperative Oncology Group Performance Status
E15	Observation:T29 Name:T30
T30	Observation-Name 293 346	Eastern Cooperative Oncology Group Performance Status
A3	Observation-Type-Value T30 clinical-score
R2	Abbrev-Of Arg1:E14 Arg2:E15	
T31	Eq-Comparison 361 371	initiation
E16	Eq-Comparison:T31 Temporal-Recency:T32
T32	Eq-Temporal-Recency 361 371	initiation
A4	Eq-Temporal-Recency-Value T32 first-time
T33	Procedure 351 360	treatment
E17	Procedure:T33 Temporality:E16
T34	Temporal-Connection 348 350	at
E18	Temporal-Connection:T34 Arg:E15 Arg2:E17
A5	Temporal-Connection-Type-Value E18 during
T35	Eq-Comparison 420 446	between 2007 and June 2016
E19	Eq-Comparison:T35 Operator:T36 Value:T7 Value2:T8
T36	Eq-Operator 420 427	between
A6	Eq-Operator-Value T36 BETWEEN
T37	Eq-Comparison 408 419	carried out
E20	Eq-Comparison:T37 Temporal-Period:T38
T38	Eq-Temporal-Period 408 419	carried out
A7	Eq-Temporal-Period-Value T38 past
T39	Eq-Comparison 510 513	one
E21	Eq-Comparison:T39 Value:T40
T40	Eq-Value 510 513	one
T41	Drug 514 522	cytokine
E22	Drug:T41 Name:T42 Minimum-Count:E21
T42	Drug-Name 514 522	cytokine
T43	Procedure 492 499	treated
E23	Procedure:T43 Temporality:E6
R4	Using Arg1:E23 Arg2:E22	
T44	Drug 524 538	Interferon α2a
E24	Drug:T44 Name:T45
T45	Drug-Name 524 538	Interferon α2a
R5	Example-Of Arg1:E24 Arg2:E22	
T9	Drug 550 563	interleukin-2
E25	Drug:T9 Name:T46 Dose:T47
T46	Drug-Name 550 563	interleukin-2
T47	Polarity 540 544	high
A8	Polarity-Value T47 high
R6	Example-Of Arg1:E25 Arg2:E22	
